Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Pharmacology Study of NS-863 in Healthy Female Subjects
jRCT2071240098Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NS-863, sponsored by Nippon Shinyaku. Primary endpoints: Plasma concentrations of triazolam, Pharmacokinetic parameters of triazolam and 4 more. Started Feb 2025; status: completed.
02
Drugs
NS-863
Beyond the preview
Go deeper on jRCT2071240098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240098.